Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
Expected Weight-Loss Results Weight loss with GLP-1 medications is steady and progressive rather than sudden
Open Medicine, 18 (1), Article 20230692
When vial-size variants exist, they remain separate because concentration and syringe-unit calculations change with vial strength
Hidradenitis suppurativa After taking a GLP-1 drugs, some HS patients reported fewer flare-ups of lumps and boils and less drainage
It is widely used in the food industry as a sweetener and humectant and in pharmaceutical formulations